Tempest Appoints Andrew Fang to Spearhead Business Development, Focus on Global Licensing and Phase 3 Asset Partnerships
TPST sits 45% above its 52-week low of $1.5 on elevated volume (3.1× avg).
Summary
Tempest Therapeutics has appointed Andrew Fang, Ph.D., as its new Head of Business Development. This strategic hire is critical for the company, which recently disclosed a 'going concern' warning and has engaged in significant share resale filings. Dr. Fang's mandate is to advance strategic partnerships, cross-border licensing, and corporate transactions, with a particular focus on securing a partner for its Phase 3-ready amezalpat program and expanding its CAR-T portfolio, especially in China. This move signals a proactive effort to secure non-dilutive funding and accelerate pipeline development, which is vital for the company's financial health and strategic pivot. Investors will be closely watching for any partnership announcements that could emerge from this appointment.
At the time of this announcement, TPST was trading at $2.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.7M. The 52-week trading range was $1.50 to $12.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.